The board of directors of Sino Biopharmaceutical Limited announced that application for marketing of the Category I anti-tumor innovative drug "TQ-B3139" developed by the Group has been submitted to and accepted by the National Medical Products Administration of the People's Republic of China. The indication for this application is the treatment of patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") who are positive for anaplastic lymphoma kinase ("ALK") and the specifications are 100mg, 125mg and 150mg.